Quick Answer
Entrada Therapeutics, Inc. reported Diluted EPS of $3.47 per share (loss) for fiscal year 2025.
Entrada Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$3.47 | -306.5% |
| 2024 | $1.68 | +940.0% |
| 2023 | -$0.20 | +93.4% |
| 2022 | -$3.02 | +63.0% |
| 2021 | -$8.16 | +66.0% |
| 2020 | -$24.00 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.06 | -202.9% | -1.9% |
| June 30, 2025 | -$1.04 | -167.1% | -147.6% |
| March 31, 2025 | -$0.42 | -161.8% | -20.0% |
| September 30, 2024 | -$0.35 | -134.3% | -122.6% |
| June 30, 2024 | $1.55 | +298.7% | +127.9% |
| March 31, 2024 | $0.68 | +423.8% | -33.3% |
| September 30, 2023 | $1.02 | +227.5% | +230.8% |
| June 30, 2023 | -$0.78 | -5.4% | -271.4% |
- Entrada Therapeutics, Inc. showed a decrease of -306.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Entrada Therapeutics, Inc.’s diluted eps has grown by 85.5% (from $24.00 per share (loss) to $3.47 per share (loss)).
- The most recent figure is from Entrada Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: